Q2 2025 Management View CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, ...

尽管业绩超预期,ResMed股价在常规交易时段大幅下跌8.33%。这一下跌可能归因于更广泛的市场趋势或投资者对未来增长前景的担忧。股价在盘后交易中略有反弹,上涨0.28%。

ResMed’s (ASX:RMD) half-year FY25 results reflect a company that is not only thriving in its core business but is also ...

Medical device company ResMed (NYSE:RMD) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on ...

Reports Q2 revenue $1.28B, consensus $1.27B. “Our second quarter fiscal year 2025 top-line growth, margin expansion, and double-digit EPS ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

I'll now turn the call over to ResMed's Chairman and CEO, Mick Farrell. Great. Thank you, Mike and good morning and good afternoon as we welcome our shareholders and review ResMed's second-quarter, ...

CEO Michael Farrell reported 10% global revenue ... aimed at improving comfort and potentially redefining market standards for CPAP masks. ResMed also collaborated with Apple Vision Pro to ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

ResMed makes continuous positive airway pressure ... as well as use of GLP-1 therapies," CEO Mick Farrell said, adding that he expects these developments to drive more patients to use their ...